Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Su Nil
- Development stage
- Unknown
- Lead developer
- Riddhi Healthcare
- Administration
- Oral
01
Overview
Su Nil is an Ayurvedic polyherbal supplement developed and manufactured by Riddhi Healthcare. It is formulated as a tablet and is primarily marketed for the management of blood sugar levels in individuals with diabetes mellitus. As a traditional Ayurvedic product, it is composed of various plant extracts known in Indian medicine for their hypoglycemic properties. The product is manufactured in a GMP-certified facility, though it is classified as a herbal or dietary supplement rather than a pharmaceutical drug with a formal clinical development pipeline or defined molecular targets.
- Brand names
- Su Nil
- Other names
- Su Nil Tablet
Beyond the preview
Go deeper on Su Nil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Su Nil.